We report the results of the third nationwide survey aimed at clarifying the clinical course of Rhododenol-induced leukoderma. The survey was performed between December 2014 and March 2015, and 981 cases were analyzed. With regard to outcome, 82% (796/964) of the cases were evaluated as improved or cured. However, 16% (156/964) of cases were evaluated as unchanged or exacerbated. In 27% (258/969) of the cases, hyperpigmentation was still observed in the affected area. 225 cases were treated with ultraviolet light irradiation that was effective in 50% of the cases. (Jpn J Dermatol 125: 2401-2414, 2015)
We treated 106 patients diagnosed with scabies and 15 persons who were family members and/or caregivers with 5% permethrin cream imported for the purpose of this study. Among the 106 patients were 41 infants, 5 pregnant women, and 11 lactating women. The subjects were prescribed with one to four doses of 5% permethrin cream for application from head to toe, with a one-week interval between each application. Sixty-three cases were treated with 2 applications, 8 cases with 3 applications. Two cases required 4 applications. Thirty-three patients were treated with a combination of permethrin and another scabicide. Of the 106 patients treated, 105 patients (99.1%) were completely cured. One patient who was taking 5 mg/day of prednisolone for treatment of systemic sclerosis, had a recurrence after one and a half months. None of the treated 121 persons showed any adverse effects to the cream such as contact dermatitis. We were able to confirm in this study that 5% permethrin cream is safe and effective for the treatment of scabies in Japan; not only in adults but also in infants and in women who are pregnant or lactating.